Part two focuses on the requirement that Part D sponsors must make enrollees aware of upcoming benefits.
The U.S. Department of Health and Human Services released the final part two guidance for the Medicare Prescription Drug Payment Plan on July 16, according to a news release on their website.
Starting in January 2025, Medicare beneficiaries will be able to spread their prescription drug costs across the calendar year rather than pay the full cost every time they go to the pharmacy.
Part one guidance was released in February of this year and focused on operational requirements for the program.
Part two of this plan was released to ensure that people with Medicare Part D drug coverage are aware of the payment options. In the new program, Medicare beneficiaries will pay nothing for covered Part D drugs. Instead, Part D sponsors will bill the beneficiaries monthly until the payment is made in full. Sponsors will then pay the pharmacies.
This program will launch at the same time as Medicare beneficiaries are having their out-of-pocket annual medication costs capped at $2,000.
Part D plan sponsors will be required to reach out to enrollees who spent at least $2,000 on drugs from January 1 and September 30 of this year.
The CMS will provide resources online that include a cost preview in the Medicare Finder. There will also be training sessions held for Medicare partners.
The CMS will also be publishing six model documents to help Part D sponsors meet their education and outreach requirements.
These changes are all part of the Inflation Reduction Act, established in 2022.
Some ways the Inflation Reduction Act has helped reduce costs so far include:
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen